Who is eligible for clinical trial NCT05853575?

Participants must meet protocol criteria for Advanced Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05853575 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-13

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575)

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Mirati Therapeutics Inc.

🩺 Plain-English Summary (8th-Grade Level)

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Who can join: Review the eligibility criteria below.

Location: Local Institution - 101 — Santa Rosa, California

Age range: 18 Years

🧪 Interventions in This Study

Adagrasib (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (98 Sites)

Showing the first 25 of 98 sites.

Local Institution - 101 — Santa Rosa, California
Local Institution - 105 — Kansas City, Missouri
Local Institution - 100 — Durham, North Carolina
Local Institution - 106 — Dallas, Texas
Local Institution - 181 — Salvador, Estado de Bahia
Local Institution - 177 — Porto Alegre, Rio Grande do Sul
Local Institution - 182 — Itajaí, Santa Catarina
Local Institution - 178 — Belo Horizonte, São Paulo
Local Institution - 102 — São Paulo,
Local Institution - 175 — São Paulo,
Local Institution - 527 — Zagreb, City of Zagreb
Local Institution - 529 — Rijeka, Primorje-Gorski Kotar County
Local Institution - 559 — Grenoble, Auvergne-Rhône-Alpes
Local Institution - 556 — Pessac, Gironde
Local Institution - 553 — Saint-Herblain, Loire-Atlantique
Local Institution - 554 — Angers, Maine-et-Loire
Local Institution - 552 — Lorient, Morbihan
Local Institution - 555 — Nantes, Pays de la Loire Region
Local Institution - 557 — Poitiers, Poitou-Charentes
Local Institution - 561 — Nice, Provence-Alpes-Côte d'Azur Region
Local Institution - 551 — Marseille, Rhône
Local Institution - 560 — Villefranche-sur-Saône, Rhône
Local Institution - 562 — Paris,
Local Institution - 558 — Quimper,
Local Institution - 550 — Saint-Mandé,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Cancer

Intrapleural Catheter Daily Versus Three Times a Week Drainage — Houston, Texas
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer — Toronto, Ontario
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer — New York, New York
FS120 Phase 1/1b Study in Patients With Advanced Malignancies — New Haven, Connecticut
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Encinitas, California

Explore by condition: All Advanced Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗